First human trial launches for DNA vaccine against deadly CCHF virus
NCT ID NCT06684431
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new DNA vaccine called N-pVAX1 against Crimean-Congo hemorrhagic fever (CCHF), a severe viral disease. Fifteen healthy adults received three doses of the vaccine over 12 weeks. The main goal was to check safety and side effects, while also measuring the immune response. Results will help decide if further studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DNA vaccine N-pVAX1
- What this could lead to
- If successful, this could lead to a safe and effective vaccine to prevent Crimean-Congo hemorrhagic fever, a severe and often fatal disease.
- What could go wrong
- This is a very early Phase 1 trial with only 15 participants, so it primarily tests safety, not effectiveness. The vaccine may not trigger a strong enough immune response or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRIMEAN-CONGO HEMORRHAGIC FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Phase I Unit, Karolinska University Hospital
Stockholm, Stockholm County, 17176, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.